Financial results for the first half of 2012 September 6, 2012 Three-year cash horizon resulting from collaboration and licensing agreement with Bristol-Myers Squibb Significant advance of the IPH21 program with the regulatory authorization to start the first...
Journée « VALEURS MOYENNES » à la SFAF (Société Française des Analystes Financiers) September 6, 2012
Journée Biotech du 20 janvier à la SFAF (Société Française des Analystes Financiers) January 20, 2012
